Clinical Trials List
2024-01-01 - 2027-12-31
Phase III
Recruiting7
ICD-10L40.50
Arthropathic psoriasis, unspecified
ICD-10L40.51
Distal interphalangeal psoriatic arthropathy
ICD-10L40.52
Psoriatic arthritis mutilans
ICD-10L40.53
Psoriatic spondylitis
ICD-10L40.54
Psoriatic juvenile arthropathy
ICD-10L40.59
Other psoriatic arthropathy
ICD-9696.0
Psoriatic arthropathy
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
-
Trial Applicant
Johnson & Johnson
-
Sponsor
Janssen Research & Development, LLC
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 吳貞宜 Division of Dermatology
- 張綜顯 Division of Dermatology
- DINGDAR LEE Division of Dermatology
- Cheng-Yuan Li Division of Dermatology
- 何翊芯 Division of Dermatology
- Yun-Ting Chang Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yu-Huei Huang Division of Dermatology
- Ya-Ching Chang Division of Dermatology
- Chun-Bing Chen Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳柏樺 Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 黃瑞雲 Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
from baseline at Week 16.
PASI 90 at Week 16.
Inclution Criteria
5. Total IGA ≥3 at screening and baseline.
6. Candidate for phototherapy or systemic treatment for plaque psoriasis.
7. Suitable candidate without contraindications for deucravacitinib treatment according
to the respective country’s approved deucravacitinib product labeling in the opinion of
the investigator.
Exclusion Criteria
2. Current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of
psoriasis from beta blockers, calcium channel blockers, or lithium).
3. A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal,
liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,
hematologic, rheumatologic, psychiatric, or metabolic disturbances.
4. Criterion modified per Global Amendment 2
4.1 Known allergies, hypersensitivity, or intolerance to JNJ-77242113,
deucravacitinib, or to any of the excipients or components of the study intervention
(refer to the JNJ-77242113 IB, the deucravacitinib label, and Protocol Section 6.1).
5. Major surgical procedure, (eg, requiring general anesthesia) within 8 weeks before
screening, or will not have fully recovered from surgical procedure, or has a surgical
procedure planned during the time the participant is expected to participate in the study.
Note: Participants with planned surgical procedures
The Estimated Number of Participants
-
Taiwan
51 participants
-
Global
750 participants
